Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonsteroidal anti-inflammatory analgesic used to relieve the pain symptoms of osteoarthritis. Its products are used in medicines, dietary supplements, and cosmetics applications. The company also engages in research and experimental development and capital market activities. The company exports its products to Europe, America, and Southeast Asia. Suzhou Fushilai Pharmaceutical Co., Ltd. was founded in 2000 and is based in Changshu, China.